Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armida D'Incecco

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Expert Opinion on Drug Safety|September 13, 2011
Gefitinib for non-small-cell lung cancer treatmentArmida D'Incecco, Federico Cappuzzo
Anti-Cancer Agents in Medicinal Chemistry|January 24, 2015
MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: MinireviewCarmelo Tibaldi, Armida D'Incecco, Alessandro Lagana
Future Oncology (London, England)|May 8, 2013
Rare mutations in non-small-cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Federico Cappuzzo
Drugs & Aging|October 9, 2015
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the ElderlyGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Biological Therapy|August 13, 2013
Targeted therapy for NSCLC with driver mutationsGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|April 22, 2014
Protein kinase inhibitors to treat non-small-cell lung cancerGabriele Minuti, Armida D'Incecco, Lorenza Landi, et al.
Current Opinion in Oncology|February 7, 2013
Targeting c-MET in the battle against advanced nonsmall-cell lung cancerLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
MET overexpression and gene amplification in NSCLC: a clinical perspectiveLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Journal of Cancer Research and Clinical Oncology|December 16, 2014
Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patientsEnrico Vasile, Carmelo Tibaldi, G Leticia Leon, et al.
Cytokine & Growth Factor Reviews|July 25, 2017
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidencesLuana Calabrò, Giovanni Luca Ceresoli, Armida D'Incecco, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Expert Opinion on Drug Safety|September 13, 2011
Gefitinib for non-small-cell lung cancer treatmentArmida D'Incecco, Federico Cappuzzo
Anti-Cancer Agents in Medicinal Chemistry|January 24, 2015
MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer: MinireviewCarmelo Tibaldi, Armida D'Incecco, Alessandro Lagana
Future Oncology (London, England)|May 8, 2013
Rare mutations in non-small-cell lung cancerManolo D'Arcangelo, Armida D'Incecco, Federico Cappuzzo
Drugs & Aging|October 9, 2015
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the ElderlyGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Biological Therapy|August 13, 2013
Targeted therapy for NSCLC with driver mutationsGabriele Minuti, Armida D'Incecco, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|April 22, 2014
Protein kinase inhibitors to treat non-small-cell lung cancerGabriele Minuti, Armida D'Incecco, Lorenza Landi, et al.
Current Opinion in Oncology|February 7, 2013
Targeting c-MET in the battle against advanced nonsmall-cell lung cancerLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Lung Cancer (Auckland, N.Z.)|February 18, 2017
MET overexpression and gene amplification in NSCLC: a clinical perspectiveLorenza Landi, Gabriele Minuti, Armida D'Incecco, et al.
Journal of Cancer Research and Clinical Oncology|December 16, 2014
Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patientsEnrico Vasile, Carmelo Tibaldi, G Leticia Leon, et al.
Cytokine & Growth Factor Reviews|July 25, 2017
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidencesLuana Calabrò, Giovanni Luca Ceresoli, Armida D'Incecco, et al.
Pageof 4